No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + panobinostat Sensitive: A1 - Approval bortezomib + panobinostat Sensitive : A1	bortezomib + panobinostat Sensitive: A1 - Approval bortezomib + panobinostat Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + ixazomib Sensitive: A1 - Approval lenalidomide + ixazomib Sensitive : A1	lenalidomide + ixazomib Sensitive: A1 - Approval lenalidomide + ixazomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib Sensitive: A1 - Approval bortezomib Sensitive : A1	bortezomib Sensitive: A1 - Approval bortezomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + carfilzomib Sensitive: A1 - Approval lenalidomide + carfilzomib Sensitive : A1	lenalidomide + carfilzomib Sensitive: A1 - Approval lenalidomide + carfilzomib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab + bortezomib Sensitive: A1 - Approval rituximab + bortezomib Sensitive : A1	rituximab + bortezomib Sensitive: A1 - Approval rituximab + bortezomib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	bortezomib Sensitive: A1 - Approval bortezomib Sensitive : A1	bortezomib Sensitive: A1 - Approval bortezomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + bortezomib Sensitive: A2 - Guideline lenalidomide + bortezomib Sensitive : A2	lenalidomide + bortezomib Sensitive: A2 - Guideline lenalidomide + bortezomib Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + elotuzumab Sensitive: A2 - Guideline bortezomib + elotuzumab Sensitive : A2	bortezomib + elotuzumab Sensitive: A2 - Guideline bortezomib + elotuzumab Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ixazomib Sensitive: A2 - Guideline ixazomib Sensitive : A2	ixazomib Sensitive: A2 - Guideline ixazomib Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2

Proteasome inhibitor

Proteasome inhibitor

Associations(149)

Associations
(149)